Europe's drug regulator, The European Medicines Agency(EMA) on Wednesday found a possible link between AstraZeneca's COVID-19 vaccine and rare blood clotting issues in adults who had received the shot. The regulator said it had taken into consideration all currently available evidence.

The regulator said that blood clots should be listed as a "very rare" side effect of the AstraZeneca coronavirus vaccine but that the jab's benefits continue to outweigh the risks. 

"EMA's safety committee has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects" of the shot, the Amsterdam-based EU drug regulator said in a statement.

The rollout of Oxford/AstraZeneca's COVID-19 vaccine to under-30s will be halted following recommendations of Britain's medicine regulator on Wednesday, local media reported, adding they would be given Pfizer or Moderna instead.